Invention Grant
- Patent Title: Enveloped virus resistant to complement inactivation for the treatment of cancer
-
Application No.: US16303729Application Date: 2018-05-10
-
Publication No.: US11274141B2Publication Date: 2022-03-15
- Inventor: Tianci Luo , Rene Molina , Gabriel Castille
- Applicant: Wellstat ImmunoTherapeutics, LLC
- Applicant Address: US MD Rockville
- Assignee: Wellstat ImmunoTherapeutics, LLC
- Current Assignee: Wellstat ImmunoTherapeutics, LLC
- Current Assignee Address: US MD Rockville
- Agent Lewis J. Kreisler
- International Application: PCT/US2018/032018 WO 20180510
- International Announcement: WO2018/209052 WO 20181115
- Main IPC: C07K19/00
- IPC: C07K19/00 ; C07K14/705 ; A61K35/768 ; A61P35/00 ; C12N15/62 ; A61K35/76 ; C12N5/16 ; A61K38/00

Abstract:
A recombinant fusion protein is disclosed. The fusion protein comprises: (a) a CD55 peptide sequence, (b) a linker sequence C-terminal to the CD55 sequence, (c) a transmembrane domain C-terminal to the linker sequence, and (d) an intracellular domain C-terminal to the transmembrane domain. The fusion protein does not contain a GPI anchor. The fusion protein can be expressed with an N-terminal secretory signal peptide, which is cleaved to yield the mature protein on the surface of a cell line or an enveloped virus. An oncolytic virus expressing the fusion protein is resistant to complement inactivation and can be used to treat cancer.
Public/Granted literature
- US20190194292A1 Enveloped Virus Resistant to Complement Inactivation for the Treatment of Cancer Public/Granted day:2019-06-27
Information query